What can we learn from clinical trials of anticonvulsant drugs in epilepsy?

European Journal of Pain

Volumn 6, Issue SUPPL. 1, 2002, Pages 35-44

  Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; PLACEBO;

CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FREQUENCY ANALYSIS; HUMAN; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; MEDICAL ETHICS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; STANDARD;

ANTICONVULSANTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; ETHICS, MEDICAL; HUMANS; META-ANALYSIS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS;

EID: 0036370370     PISSN: 10903801     EISSN: None     Source Type: Journal    
DOI: 10.1053/eujp.2001.0320     Document Type: Review

References (56)

1. Besag FMC, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39: 183-187.
2. Bill P, Vigonius U, Pohlmann H, Guerreiro C, Kochen S, Saffer D, Moore A. A double-blind, controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195-204.
3. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476-479.
4. Brodie MJ, Overstall PW, Giorgi L, the UK Lamotrigine Elderly Study Group. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999; 37: 81-87.
5. Castillo S, Schmidt D, White S. Oxcarbazepine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2000; CD 2028.
6. Chadwick D, for the Vigabatrin European Monotherapy Study Group. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: A multicentre randomised double-blind study. Lancet 1999; 354: 13-19.
7. Chadwick DW, Marson AG. Zonisamide for drug resistant partial epilepsy. Cochrane Database Systm Rev 2000: CD 001416.
8. Chadwick DW, Anhut H, Greiner MJ, Alexander J, Murray GH, Garofalo EA, Pierce MW, for the International Gabapentin Monotherapy Study Group 945-77. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 1998; 51: 1282-1288.
9. Chaesiwikul R, Privitera MP, Hutton JL, Marson AF. Levetiracetam for drug-resistant partial seizures: a systematic review with meta-analysis. Epilepsia 2000; 41 (Suppl. 4th European Congress on Epileptology, Firenze 7-12 October 2000): 39.
10. Christe W, Kramer G, Vigonius U, Pohlmann H, Steinhoff BJ, Brodie MJ, Moore A. A double-blind, controlled clinical trial of oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451-460.
11. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson R. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999; 40: 590-600.
12. Dam M, Ekberg R, Lovning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-76.
13. De Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BGR, Johnson AL, Reynolds EH. Randomized comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-713.
14. Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox-Gastaut syndrome). Epilepsia 1997; 38: 68-73.
15. Elferink JA, Van Zwieten-Boot BJ. New antiepileptic drugs. Analysis of number needed to treat shows differences between drugs studied. BMJ 1997; 314: 603.
16. Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs 1995; 50: 691-713.
17. Fleiss J. Statistical Methods for Rates and Proportions. New York: John Wiley & Sons, 1973.
18. Gatti G, Bonomi I, Jannuzzi G, Perucca E. The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharmacol Design 2000; 6: 617-638.
19. Guerreiro M, Vigonius U, Pohlmann H, De Manreza M, Fejuerman N, Antoniuk S, Moore A. A double-blind, controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27: 205-213.
20. Heller AJ, Chesterman P, Elwes RDC, Crawford P, Chadwick D, Johnson AL, Reynolds EH. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomized comparative monotherapy trial. J Neurol Neurosurg Psych 1995; 58: 44-50.
21. Hills M, Armitage P. The two paired cross-over trial. Br J Clin Pharmacol 1979; 8: 7-20.
22. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy: A randomized controlled study. Arch Neurol 1995; 52: 989-996.
23. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. Therapeutic-class wars. Drug promotion in a competitive marketplace. NEJM 1994; 331: 1353.
24. Leach JP. Polypharmacy with anticonvulsants. Focus on synergism. CNS Drugs 1997; 8: 366-375.
25. Leber P. Hazards of inference. The active control investigation. Epilepsia 1983; 30: S57-S63.
26. Lesaffre E, Boon P, Pledger GW. The value of the number-needed-to-treat method in antiepileptic drug trials. Epilepsia 2000; 41: 440-446.
27. Marson AG, Kadir ZA, Button LJ, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38: 859-880.
28. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB, Homan R, Crill WE, Lubozynski MF, Rosenthal NP, Mayersdorf A. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. NEJM 1985; 13: 145-151.
29. Mattson RH, Cramer JA, Collins JF, and the Department of the Veteran Affairs Epilepsy Cooperative Study Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. NEJM 1992; 327: 765-771.
30. Mawer GE, Jamieson V, Lucas SB, Wild JM. Adjustment of carbamazepine dose to offset remacemide interactions. Epilepsia 1996; 37 (Suppl. 4): 6.
31. Motte J, Trevathan E, Arvidsson JFV, Barrera MN, Mullens EL, Manasco P, and the Lamictal Lennox-Gastaut Study Group. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. NEJM 1997; 337: 1807-1812.
32. Naime A, Smith D, Nightingale S. Lamotrigine versus physician's choice in epilepsy monotherapy. Epilepsia 1998; 39 (Suppl 2.): 62.
33. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996a; 42: 531-543.
34. Perucca E. Principles of drug treatment. In: Shorvon SD, Dreifuss F, Fish D, Thomas D, eds. The Treatment of Epilepsy. Oxford: Blackwell Science, 1996b: 152-168.
35. Perucca E. Evaluation of drug treatment outcome in epilepsy: a clinical perspective. Pharm World Sci 1997; 19: 217-222.
36. Perucca E. Innovative monotherapy trial designs for the assessment of antiepileptic drugs: a critical appraisal. Eur J Clin Pharmacol 1998; 54: 1-6.
37. Perucca E. Drugs under clinical trial. In: Eadie MJ, Vajda FJE, eds. Antiepileptic Drugs Pharmacology and Therapeutics, Handbook of Experimental Pharmacology, Vol. 138. Berlin: Springer Verlag, 1999: 515-551.
38. Perucca E. Clinical pharmacology and therapeutic use of new antiepileptic drugs. Fundam Clin Pharmacol 2002 (in press).
39. Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 1999; 33: 247-262.
40. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening of seizures. Epilepsia 1998; 39: 5-17.
41. Perucca E, Beghi E, Dulac O, Shorvon S, Tomson T. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000; 41: 107-139.
42. Perucca E, Dulac O, Shorvon SD, Tomson T. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs 2001; 15: 609-612.
43. Privitera MD, Treiman DM, Pledger GW, Sahlroot JT, Handforth A, Linde MS, France CR, Cereghino JJ, McCutchen CB, Wood JH. Dezinamide for partial seizures: results of an n-of-1 design trial. Neurology 1994; 44: 1453-1458.
44. Reunanen M, Dam M, Yuen AWC. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996; 23: 149-155.
45. Richens A, Davidson DLW, Cartlidge NEF, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult-onset epilepsy. J Neurol Neurosurg Psychiatr 1994; 57: 682-687.
46. Rosenzweig P, Miget N, Brohier S. Transamonase elevation on placebo during Phase I trials: Prevalence and significance. Br J Clin Pharmacol 1999; 48: 19-23.
47. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based Medicine: How to Practice and Teach EBM. New York: Churchill-Livingstone, 1997.
48. Schachter SC, Vazquez B, Fisher RS, Laxer KD, Montouris GD, Combs-Cantrell DT, Faught E, Willmore LJ, Morris GL, Ojemann L, Bennett D, Messenbrink P, D'Souza J, Kramer L. Oxcarbazepine: double-blind, randomized, placebo- control, monotherapy trial for partial seizures. Neurology 1999; 10: 732-737.
49. Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of children with epilepsy. Epilepsia 1994; 35: 359-367.
50. Spilker B, Segretti A. Validation of the phenomenon of regression of seizure frequency in epilepsy. Epilepsia 1984; 25: 443-449.
51. Steiner TJ, Dellaportas CI, Findley LJ, Gross M, Gibberd FB, Perkin GD, Park DM, Abbott R. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40: 601-606.
52. Tanganelli P, Regesta G. Vigabatrin versus carbamazepine monotherapy in newly diagnosed epileptics. A randomized response conditional cross-over study. Epilepsy Res 1996; 25: 257-262.
53. Timmings PL, Richens A. Lamotrigine as add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992; 32: 305-307.
54. Verity CM, Hosking G, Easter DJ, on behalf of the Pediatric EPITEG Collaborative Group. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995; 37: 97-108.
55. Walker MC, Sander JWAS. Difficulties in extrapolating from clinical trials to clinical practice: the case of antiepileptic drugs. Neurology 1997; 49: 333-337.
56. Zamponi N, Cadinali C. Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Arch Neurol 1999; 56: 605-707.